Emergent BioSolutions Inc. is planning to open a new Michigan facility to expand production of its BioThrax anthrax vaccine.
The Detroit Free Press reports Monday that the Rockville, Md.-based company says it could take until 2014 or 2015 until the Lansing facility completes a review by the U.S. Food and Drug Administration and receives certification.
CEO and President Daniel Abdun-Nabi says large-scale production has been a challenge and the expansion will help meet that goal.
Emergent BioSolutions announced in 2011 that the U.S. government formally ordered 44.8 million doses of BioThrax anthrax vaccine in an agreement worth as much as $1.25 billion over five years.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or firstname.lastname@example.org.